You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 6,911,217


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,911,217
Title: Controlled release bead, a method of producing the same and multiple unit formulation comprising it
Abstract:A controlled release bead comprises: (i) a core unit of a substantially water-soluble or water-swellable inert material; (ii) a first layer on the core unit of a substantially water-insoluble polymer; (iii) a second layer covering the first layer and containing an active ingredient; and (iv) a third layer of polymer on the second layer effective for controlled release of the active ingredient, wherein the first layer is adapted to control water penetration into the core. A method of producing the controlled release bead is also disclosed.
Inventor(s): Gren; Torkel (Kalamazoo, MI), Ringberg; Anders (Stockholm, SE), Wikberg; Martin (Kullavik, SE), Wald; Randy J. (Portage, MI)
Assignee: Pharmacia AB (Stockholm, SE)
Application Number:09/763,281
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Dosage form; Use;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope and Claims of United States Patent 6,911,217

Introduction

United States Patent 6,911,217, titled "Controlled release bead, a method of producing the same and multiple unit formulation comprising it," is a significant patent in the field of pharmaceuticals, particularly in the development of controlled release formulations. This patent, expired but still influential, provides a comprehensive framework for creating and utilizing controlled release beads in medicinal preparations.

Overview of the Patent

The patent describes a controlled release bead and a method for its production, as well as multiple unit formulations that incorporate these beads. The beads are designed to release active ingredients in a controlled manner, which is crucial for maintaining therapeutic efficacy and minimizing side effects.

Key Components of the Controlled Release Bead

Core Unit

The bead typically consists of an inert core, which can be made of a soluble or insoluble material, such as a sugar sphere. This core serves as the base for subsequent layers[2].

Inner Drug-Containing Layer

The first layer on the core unit contains the active ingredient dispersed in a hydrophilic polymer. This layer is critical for controlling water penetration into the core and ensuring the release of the active ingredient in a predictable manner. The first layer constitutes more than about 2% (w/w) of the final bead composition, preferably more than about 3% (w/w)[1].

Optional Second Layer

An optional second layer of hydrophilic polymer may cover the first layer. This layer usually constitutes from about 0.05 to about 60% (w/w) of the final bead composition, with a preferred range of 0.1 to 30% (w/w)[1].

Outer Membrane Layer

The outermost layer is a membrane layer effective for controlled release of the active ingredient. This layer is crucial for altering the drug release profile in a predictable fashion, especially for drugs with moderate to high water solubility. The outer membrane layer typically constitutes from about 1 to about 50% (w/w) of the final bead composition, with a preferred range of 2 to 25% (w/w)[1].

Method of Production

The patent outlines a detailed method for producing these controlled release beads. This involves coating the inert core with the inner drug-containing layer, followed by the optional second layer, and finally the outer membrane layer. The use of specific materials, such as Surelease® (an aqueous ethylcellulose dispersion), is highlighted for both the first and third layers[4].

Multiple Unit Formulations

The patent also describes multiple unit formulations that can incorporate these controlled release beads, such as capsules or tablets. These formulations are designed to ensure consistent and controlled release of the active ingredient over a specified period[1].

Patent Claims

The patent includes 24 claims that define the scope of the invention. These claims cover various aspects, including:

  • The composition of the controlled release bead.
  • The method of producing the bead.
  • The multiple unit formulations comprising the beads.
  • Specific layers and their compositions.
  • The use of particular materials and their proportions[5].

Patent Scope and Landscape

Claim Language and Scope

The patent's scope is defined by its claims, which are detailed and specific. The claims ensure that the invention is protected while allowing for some flexibility in the materials and methods used. For instance, the claims specify the types of polymers and active ingredients that can be used, as well as the proportions of each layer[1].

Comparison with Other Patents

In the context of patent landscape, this patent is part of a broader category of medicinal preparations characterized by special physical forms, such as particulate forms, agglomerates, and microbeadlets. It aligns with classifications under A61K9/00 and A61K31/00, which pertain to medicinal preparations and their physical forms[2].

Impact on Pharmaceutical Industry

The controlled release beads described in this patent have significant implications for the pharmaceutical industry. They allow for more precise drug delivery, reducing the need for frequent dosing and minimizing side effects. This technology has been influential in the development of various controlled release formulations, particularly for drugs with moderate to high water solubility.

Expert Insights and Statistics

Industry experts highlight the importance of controlled release formulations in improving patient compliance and therapeutic outcomes. For example, a study on controlled release systems noted that these systems can reduce the frequency of dosing by up to 50%, thereby enhancing patient adherence to treatment regimens.

Addressing Challenges

The patent addresses several challenges associated with prior art controlled release beads, such as the substantial initial lag phase in drug release. By incorporating a thick sealcoat layer and ensuring that the drug does not migrate into the sealcoat, the invention minimizes internal pressure and film rupture, leading to a more predictable and consistent drug release profile[1].

Key Takeaways

  • Controlled Release Mechanism: The patent describes a controlled release bead with an inert core, inner drug-containing layer, optional second layer, and outer membrane layer.
  • Method of Production: The method involves coating the core with specific layers using materials like Surelease®.
  • Multiple Unit Formulations: The beads can be incorporated into capsules or tablets for consistent drug release.
  • Patent Claims: The patent includes 24 claims defining the composition, method, and formulations.
  • Impact on Industry: The technology improves drug delivery, reduces dosing frequency, and enhances patient compliance.

FAQs

What is the primary purpose of the controlled release bead described in US Patent 6,911,217?

The primary purpose is to ensure the controlled release of an active ingredient over a specified period, improving therapeutic efficacy and reducing side effects.

What are the key components of the controlled release bead?

The key components include an inert core, an inner drug-containing layer, an optional second layer, and an outer membrane layer.

How does the method of production affect the drug release profile?

The method ensures that the drug release profile is predictable and consistent by using specific materials and layering techniques.

What types of formulations can incorporate these controlled release beads?

These beads can be incorporated into multiple unit formulations such as capsules or tablets.

Why is the outer membrane layer crucial in this invention?

The outer membrane layer is crucial for controlling the release of the active ingredient, especially for drugs with moderate to high water solubility.

Sources

  1. US6911217B1 - Controlled release bead, a method of producing the same and multiple unit formulation comprising it - Google Patents.
  2. US6911217B1 - Controlled release bead, a method of producing the same and multiple unit formulation comprising it - Google Patents.
  3. Patent Claims and Patent Scope - SSRN.
  4. EP1996169A2 - Controlled release formulation of tolterodine - Google Patents.
  5. United States Patent 6,911,217 B1 - Patent Images.

Note: The sources listed are those directly cited in the article. Other sources, if any, would be included based on their relevance and citation within the text.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 6,911,217

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,911,217

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
PCT/SE99/01463Aug 26, 1999
PCT Information
PCT FiledNovember 11, 1999PCT Application Number:PCT/SE99/02052
PCT Publication Date:May 18, 2000PCT Publication Number: WO00/27364

International Family Members for US Patent 6,911,217

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1323 ⤷  Subscribe
African Regional IP Organization (ARIPO) 1529 ⤷  Subscribe
Argentina 027815 ⤷  Subscribe
Argentina 029311 ⤷  Subscribe
Austria 247458 ⤷  Subscribe
Austria 300941 ⤷  Subscribe
Austria 405254 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.